Petrillo P, Kowalski J, Sbacchi M, Tavani A
Istituto di Richerche Farmacologiche Mario Negri, Milano, Italy.
J Recept Res. 1992;12(1):39-57. doi: 10.3109/10799899209066023.
Binding sites were characterized in rat whole spinal cord crude membrane preparations using selective labelling techniques with multiple methods of mathematical analysis of experimental curves. Mathematical analysis of single [3H]-[D-Ala2,MePhe4,Gly-ol5] enkephalin (DAGO) saturation curves suggested binding of the [3H]-ligand at one site, while displacement curves of low concentrations of [3H]-DAGO with selective mu-ligands indicated the presence of high- and low-affinity sites. All the [3H]-DAGO curves processed simultaneously by LIGAND analysis showed the presence of high (27%) and low (73%) affinity components, with a total Bmax of 3.19 pmol/g tissue. Eighty percent of [3H]-[D-Ala2,D-Leu5] enkephalin (DADLE) binding was displaced by DAGO with high affinity, indicating that a high percentage of [3H]-DADLE binding was at mu-sites. Saturation curves of [3H]-DADLE after inhibition of mu-sites by unlabelled DAGO (delta-sites) were monophasic with non-linear fitting analysis and the Bmax was 0.90 pmol/g tissue. Most mathematical analysis of single saturation curves of [3H]-(-)-bremazocine indicated binding at more than one site. DAGO, DADLE, U-69,593 and PD 117302 displaced 0.15 nM of [3H]-(-)-bremazocine biphasically: the percentages of displacement calculated with the non-linear fitting program were respectively 50 (mu-sites), 64 ((mu + delta)-sites), 18 and 25 (kappa-sites). Haloperidol displaced [3H]-(-)-bremazocine only at microM concentrations. suggesting no binding at sigma-sites. In the presence of 225 nM of DAGO, DADLE displaced only 21% of [3H]-(-)-bremazocine 0.15 nM binding (delta-sites). Most mathematical analysis of saturation curves of [3H]-(-)-bremazocine, after inhibition of binding at mu- and delta-sites by DAGO and DADLE, still indicated binding at more than one site and the selective kappa-ligands U-69,593 and PD 117302 displaced [3H]-(-)-bremazocine in these experimental conditions. LIGAND analysis of saturation and inhibition curves of [3H]-(-)-bremazocine by U-69,593 and PD 117302 showed the presence of high (43%) and low (57%) affinity components, with a total Bmax of 2,73 pmol/g tissue. Thus in rat spinal cord there are at least two mu-sites bound by [3H]-DAGO which amount together to approximately 47% of total opioid sites, delta-sites bound by [3H]-DADLE amounting to approximately 13%, kappa-sites and other unknown sites (possibly a kappa-subtype) bound by [3H]-(-)-bremazocine, which together are approximately 40% of total opioid sites.
利用选择性标记技术并结合实验曲线的多种数学分析方法,对大鼠全脊髓粗膜制剂中的结合位点进行了表征。对单条[³H]-[D-Ala²,MePhe⁴,Gly-ol⁵]脑啡肽(DAGO)饱和曲线的数学分析表明,[³H]-配体在一个位点结合,而低浓度[³H]-DAGO与选择性μ-配体的置换曲线表明存在高亲和力和低亲和力位点。通过LIGAND分析同时处理所有[³H]-DAGO曲线,结果显示存在高亲和力(27%)和低亲和力(73%)成分,总Bmax为3.19 pmol/g组织。80%的[³H]-[D-Ala²,D-Leu⁵]脑啡肽(DADLE)结合被DAGO以高亲和力置换,这表明高比例的[³H]-DADLE结合位于μ-位点。在用未标记的DAGO抑制μ-位点(δ-位点)后,[³H]-DADLE的饱和曲线经非线性拟合分析呈单相,Bmax为0.90 pmol/g组织。对[³H]-(-)-布马佐辛单条饱和曲线的大多数数学分析表明,其在多个位点结合。DAGO、DADLE、U-69,593和PD 117302以双相方式置换0.15 nM的[³H]-(-)-布马佐辛:用非线性拟合程序计算的置换百分比分别为50%(μ-位点)、64%((μ + δ)-位点)、18%和25%(κ-位点)。氟哌啶醇仅在微摩尔浓度下置换[³H]-(-)-布马佐辛,表明在σ-位点无结合。在存在225 nM DAGO的情况下,DADLE仅置换21%的0.15 nM [³H]-(-)-布马佐辛结合(δ-位点)。在用DAGO和DADLE抑制μ-和δ-位点的结合后,对[³H]-(-)-布马佐辛饱和曲线的大多数数学分析仍表明其在多个位点结合,并且在这些实验条件下,选择性κ-配体U-69,593和PD 117302置换了[³H]-(-)-布马佐辛。通过U-69,593和PD 117302对[³H]-(-)-布马佐辛的饱和和抑制曲线进行LIGAND分析,结果显示存在高亲和力(43%)和低亲和力(57%)成分,总Bmax为2.73 pmol/g组织。因此,在大鼠脊髓中,至少有两个与[³H]-DAGO结合的μ-位点,其总和约占总阿片样物质位点的47%,与[³H]-DADLE结合的δ-位点约占1